[go: up one dir, main page]

ES2134346T3 - Virus citopatico para el tratamiento y la profilaxis de la neoplasia. - Google Patents

Virus citopatico para el tratamiento y la profilaxis de la neoplasia.

Info

Publication number
ES2134346T3
ES2134346T3 ES94910177T ES94910177T ES2134346T3 ES 2134346 T3 ES2134346 T3 ES 2134346T3 ES 94910177 T ES94910177 T ES 94910177T ES 94910177 T ES94910177 T ES 94910177T ES 2134346 T3 ES2134346 T3 ES 2134346T3
Authority
ES
Spain
Prior art keywords
replication phenotype
cells
neoplastic cells
viral
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910177T
Other languages
English (en)
Inventor
Francis Mccormick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Pharmaceuticals Inc
Original Assignee
Onyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharmaceuticals Inc filed Critical Onyx Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2134346T3 publication Critical patent/ES2134346T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN METODOS Y COMPOSICIONES PARA TRATAR CONDICIONES NEOPLASTICAS MEDIANTE TERAPIA BASADA EN VIRUS. SE ADMINISTRAN DE VIRUS MUTANTES QUE CARECEN DE PROTEINAS VIRALES QUE SE UNEN Y/O INACTIVAN P 53 O RB A UN PACIENTE QUE TENGA UN NEOPLASMA QUE COMPRENDA CELULAS QUE CAREZCAN DE FUNCION P 53 Y/O RB. LOS VIRUS MUTANTES SON CAPACES DE PRODUCIR SUBSTANCIALMENTE UN FENOTIPO DE REPLICACION EN LAS CELULAS NEOPLASTICAS PERO SON SUBSTANCIALMENTE INCAPACES DE PRODUCIR UN FENOTIPO DE REPLICACION EN CELULAS NO REPLICANTES, NO NEOPLASTICAS QUE TENGAN UNA FUNCION P 53 Y/O RB ESENCIALMENTE NORMAL. LA GENERACION PREFERENCIAL DEL FENOTIPO DE REPLICACION EN LAS CELULAS NEOPLASTICAS DA COMO RESULTADO UNA MUERTE PREFERENCIAL DE LAS CELULAS NEOPLASTICAS, TANTO DIRECTAMENTE O MEDIANTE LA EXPRESION DE UN GEN CITOTOXICO EN LAS CELULAS QUE EXPRESAN UN FENOTIPO DE REPLICACION VIRAL.
ES94910177T 1993-02-16 1994-02-16 Virus citopatico para el tratamiento y la profilaxis de la neoplasia. Expired - Lifetime ES2134346T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1752593A 1993-02-16 1993-02-16

Publications (1)

Publication Number Publication Date
ES2134346T3 true ES2134346T3 (es) 1999-10-01

Family

ID=21783090

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94910177T Expired - Lifetime ES2134346T3 (es) 1993-02-16 1994-02-16 Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
ES98121753T Expired - Lifetime ES2157109T3 (es) 1993-02-16 1994-02-16 Virus citopaticos para el tratamiento y la profilasis de la neoplasia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98121753T Expired - Lifetime ES2157109T3 (es) 1993-02-16 1994-02-16 Virus citopaticos para el tratamiento y la profilasis de la neoplasia.

Country Status (11)

Country Link
EP (2) EP0931830B1 (es)
JP (2) JP3556666B2 (es)
AT (2) ATE199568T1 (es)
AU (1) AU682854B2 (es)
CA (1) CA2152941C (es)
DE (2) DE69417734T2 (es)
DK (2) DK0689447T3 (es)
ES (2) ES2134346T3 (es)
GR (2) GR3030385T3 (es)
PT (1) PT931830E (es)
WO (1) WO1994018992A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
ES2196026T3 (es) 1993-04-30 2003-12-16 Wellstat Biologics Corp Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2206179C (en) * 1994-11-28 2007-10-23 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
CA2230852A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
AU4592697A (en) * 1996-09-24 1998-04-17 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
WO1998022608A2 (en) * 1996-11-18 1998-05-28 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
US6080578A (en) * 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
EP1121442A2 (en) * 1998-10-15 2001-08-08 CANJI, Inc. Recombinant e1a deleted adenoviral vectors
IL142337A0 (en) * 1998-10-15 2002-03-10 Canji Inc Selectively replicating viral vectors
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US20020037274A1 (en) * 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
GB9906815D0 (en) * 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
PT1230378E (pt) * 1999-11-15 2007-09-17 Onyx Pharma Inc ''adenovírus oncolítico''
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
JP2004536572A (ja) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
AU2003242585A1 (en) * 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
AU2011221393A1 (en) * 2002-05-27 2011-09-29 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
JP4988199B2 (ja) * 2002-10-15 2012-08-01 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
PL1649023T3 (pl) 2003-07-21 2009-01-30 Transgene Sa Polipeptyd o podwyższonej aktywności deaminazy cytozyny
JP2007511211A (ja) * 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI1006179A2 (pt) 2009-01-13 2016-02-23 Transgène S A uso de uma fração de ácidos nucleicos mitocondriais, composição adjuvante, composição de vacina, e, kit da parte
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR20240093758A (ko) 2017-04-21 2024-06-24 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells

Also Published As

Publication number Publication date
DK0689447T3 (da) 1999-10-18
DE69426841T2 (de) 2001-09-06
ATE178490T1 (de) 1999-04-15
DE69426841D1 (de) 2001-04-12
EP0689447B1 (en) 1999-04-07
AU6272294A (en) 1994-09-14
EP0931830B1 (en) 2001-03-07
ATE199568T1 (de) 2001-03-15
JP2004115543A (ja) 2004-04-15
CA2152941C (en) 2003-04-22
AU682854B2 (en) 1997-10-23
CA2152941A1 (en) 1994-09-01
PT931830E (pt) 2001-08-30
EP0931830A3 (en) 2000-07-12
JP3556666B2 (ja) 2004-08-18
GR3030385T3 (en) 1999-09-30
JPH08507076A (ja) 1996-07-30
GR3035914T3 (en) 2001-08-31
DE69417734D1 (de) 1999-05-12
EP0689447A4 (en) 1997-06-04
EP0689447A1 (en) 1996-01-03
DE69417734T2 (de) 1999-10-07
WO1994018992A1 (en) 1994-09-01
EP0931830A2 (en) 1999-07-28
ES2157109T3 (es) 2001-08-01
DK0931830T3 (da) 2001-06-11

Similar Documents

Publication Publication Date Title
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
WO1998029555A3 (en) Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
LU93101I2 (fr) Imlygic-talimogene laherparepvec
WO1995032298A3 (en) Safe vectors for gene therapy
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
AU1062092A (en) Sulfonic stilbene derivatives in the treatment of viral diseases
DE68906735D1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
NO940810L (no) Behandling av virusinfeksjoner
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
AU696629B2 (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases
DE69422980D1 (de) Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen
AU3713489A (en) Non-reverting rna viruses
AU630249B2 (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
TW251235B (en) Treatment of viral infections

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 689447

Country of ref document: ES